Do you recommend using a ctDNA assay for a patient with HER2+ metastatic breast cancer in a continued CR to guide decision about whether to stop anti therapy?
Answer from: Medical Oncologist at Academic Institution
This is a good question and is not a rare situation in the management of HER2+ metastatic breast cancer. Radiographic complete response occurs with first-line treatment in 6-15% (CLEOPATRA, GIM-14, and other trials). Currently, the standard of care is to continue anti-Her2 therapy indefinitely. Howe...
Comments
Medical Oncologist at Shoshanna Medical Consulting LLC Thank you. Do you know if ctDNA is being looked at...
Medical Oncologist at UC San Diego School of Medicine I have done this in 2 patients who have been in co...
Thank you. Do you know if ctDNA is being looked at...
I have done this in 2 patients who have been in co...